Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumosa Therapeutics Co has the GF Score of 70, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Lumosa Therapeutics Co
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Lumosa Therapeutics Co (ROCO:6535) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Lumosa Therapeutics Co GF Score Related Terms
ROCO:6535 vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's GF Score distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's GF Score falls into.
Lumosa Therapeutics Co (ROCO:6535) has a GF Score of 70 as of Jul. 15, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Lumosa Therapeutics Co and its competitors. This is 40% above median its historical median of 50.00. Over the past decade, Lumosa Therapeutics Co's GF Score has ranged from 6.00 to 77.00.
Is Lumosa Therapeutics Co's GF Score too high?
Lumosa Therapeutics Co's current GF Score of 70 is 40% above median its 10-year median of 50.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 77.00. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's GF Score compare to VRTX and REGN?
Lumosa Therapeutics Co's GF Score of 70 can be compared against companies in the Biotechnology industry. Historically, Lumosa Therapeutics Co's own GF Score has ranged from 6.00 to 77.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current GF Score is 70, which is 40% above median its own 10-year median of 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$131.29, compared to a current price of NT$95.60 — trading 27.2% below its estimated fair value. The current GF Score is 70, which is 40% above median its 10-year median of 50.00. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current GF Score is 70 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$95.60 is trading 27.2% below its estimated GF Value™ of NT$131.29.
GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.
Key valuation signals for ROCO:6535:
GF Score: 70 (40% above median its 10-year median of 50.00)
GF Value™: NT$131.29 vs. price of NT$95.60 (27.2% below fair value)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score
Get the complete analysis for ROCO:6535
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
